VBI Vaccines And Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention And Treatment In License And Collaboration Agreements For Up To $437M Plus Royalties
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines and Brii Biosciences have expanded their partnership to address both prevention and treatment of Hepatitis B. Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri® in the Asia Pacific region. VBI will receive $15 million in upfront payments, including a $3 million equity investment, and is eligible to receive up to $422 million in additional potential regulatory and commercial milestone payments, plus double-digit royalties.
July 05, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VBI Vaccines has expanded its partnership with Brii Biosciences, which includes a $15 million upfront payment and potential for $422 million in additional payments. This could significantly boost VBI's revenues.
The expanded partnership with Brii Biosciences, including the upfront payment and potential for significant additional payments, represents a major revenue opportunity for VBI Vaccines. This is likely to be viewed positively by investors and could drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100